Surprising specificity of LY294002 in inhibiting IL-6 but not TRAF-1 expression is encouraging as inhibitors with similar properties can be used to reduce invasion of breast cancer cells, more so of ERα-positive cancer cells, by specifically reducing IL-6 expression. This evidence concerns the gene ESR1 and breast carcinoma.